Albert J. Robichaud's most recent trade in Sage Therapeutics Inc was a trade of 16,720 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 16,720 | 16,720 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 3,375 | 146,680 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.16 per share. | 03 Feb 2023 | 1,127 | 145,553 (0%) | 0% | 44.2 | 49,768 | Common Stock |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 13,300 | 13,300 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2021 | 3,800 | 143,735 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.29 per share. | 19 Oct 2021 | 1,116 | 142,619 (0%) | 0% | 40.3 | 44,964 | Common Stock |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,000 | 140,795 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.80 per share. | 15 Jun 2021 | 1,144 | 139,651 (0%) | 0% | 58.8 | 67,267 | Common Stock |
| Sage Therapeutics Inc | Albert J. Robichaud | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) |